RDD Pharma

Nov 13, 2019

RDD Pharma Enters into Non-Binding Letter of Intent to Acquire Naia Rare Diseases, Strengthening Gastroenterology Orphan Disease Pipeline

Jul 17, 2018

RDD Pharma Announces IND Clearance to Advance RDD-0315 to Treat Fecal Incontinence in Patients with Spinal Cord Injury

Jun 04, 2018

RDD Pharma Appoints Dr. Mark Sirgo as Board Chairman

Jan 04, 2018

RDD Pharma Completes Enrollment in European Phase 3 Clinical Trial for Chronic Anal Fissure

Nov 16, 2017

RDD Pharma Raises $9.5M in Series B Funding to Fuel Global Development

Sep 14, 2017

RDD Pharma Awarded Department of Defense CDMRP Grant for Clinical Development of RDD-0315 in Spinal Cord Injury Patients

Jul 05, 2017

RDD Pharma Receives Orphan Designation for RDD-0315 in Spinal Cord Injury Patients in the European Union